Covered recipient · General Payments record
VISHNU HALTHORE
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
General Payments · PY2022–2024
$1,621.61
- Reported across 35 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $497.02 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| EMD Serono, Inc. | $275.75 | 8 |
| Neurelis, Inc. | $49.46 | 2 |
| Biogen, Inc. | $39.08 | 2 |
| SK Life Science, Inc. | $34.82 | 1 |
| Lundbeck LLC | $31.36 | 1 |
| Genentech USA, Inc. | $25.24 | 1 |
| TG THERAPEUTICS, INC. | $23.25 | 1 |
| Octapharma USA, Inc. | $18.06 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Biogen, Inc. | $23.19 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104815681 | CMS |
| Biogen, Inc. | $15.89 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104854610 | CMS |
| EMD Serono, Inc. | $124.84 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120214818 | CMS |
| EMD Serono, Inc. | $24.24 | 02/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120231631 | CMS |
| EMD Serono, Inc. | $1.00 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120247035 | CMS |
| EMD Serono, Inc. | $21.26 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120247453 | CMS |
| EMD Serono, Inc. | $14.42 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120248099 | CMS |
| EMD Serono, Inc. | $21.09 | 07/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120251716 | CMS |
| EMD Serono, Inc. | $24.28 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120269818 | CMS |
| EMD Serono, Inc. | $44.62 | 12/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120277500 | CMS |
| Genentech USA, Inc. | $25.24 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133130622 | CMS |
| Lundbeck LLC | $31.36 | 01/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145922516 | CMS |
| Neurelis, Inc. | $23.82 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145642972 | CMS |
| Neurelis, Inc. | $25.64 | 04/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145642974 | CMS |
| Octapharma USA, Inc. | $18.06 | 01/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142315186 | CMS |
| SK Life Science, Inc. | $34.82 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154140344 | CMS |
| TG Therapeutics, Inc. | $23.25 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136872629 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.